(GTHX) – Hot FDA News
-
G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib
-
G1 Therapeutics (GTHX) Announces FDA Approves its COSELA: The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
-
-
Back to GTHX Stock Lookup